All-cause mortality of insulin plus dipeptidyl peptidase-4 inhibitors in persons with type 2 diabetes

BMC Endocrine Disorders

Table 1 Demographics and comorbidities in the study group and the control group

Variables	Accepted DPP-4 inhibitors				p-value
	No		Yes
	(n = 1560)		(n = 1560)
	N	%	n	%
Sex					0.8545^a
Female	614	39.36	609	39.04
Male	946	60.64	951	60.96
Age, years					0.0919^a
18–39 years	344	22.05	314	20.13
40–64 years	1065	68.27	1119	71.73
more than 65 years	151	9.68	127	8.14
Age, Mean (SD)^b	49.23 (11.77)		49.21 (11.00)		0.9573^b
Comorbidity
Ischemic heart disease	133	8.53	136	8.72	0.8483^a
Hypertension	512	32.82	509	32.63	0.9089^a
Dyslipidemia	327	20.96	327	20.96	0.99^a
Other drugs
Biguanides	1546	99.10	1546	99.10	0.99^a
Sulfonylureas	1510	96.79	1494	95.77	0.13^a
Thiazolidinediones	680	43.59	680	43.59	0.99^a
Alpha glucosidase inhibitors	628	40.26	666	42.69	0.1673^a
Duration between initial date of diagnosis of diabetes and index days (mean, median)	2531 (2530)		2504 (2562)		0.5059^b

ISSN: 1472-6823